Literature DB >> 19965814

Pulmonary vascular remodeling correlates with lung eggs and cytokines in murine schistosomiasis.

Alexi Crosby1, Frances M Jones, Mark Southwood, Susan Stewart, Ralph Schermuly, Ghazwan Butrous, David W Dunne, Nicholas W Morrell.   

Abstract

RATIONALE: Schistosomiasis is considered to be the most common worldwide cause of pulmonary hypertension. At present there is no well-characterized animal model to study the pathobiology of this important condition.
OBJECTIVES: To develop a mouse model of schistosomiasis, characterize the extent of pulmonary vascular remodeling, and determine the potential role of inflammatory cytokines.
METHODS: Mice (C57/Bl6) were infected transcutaneously with a high dose (approximately 75-100 cercariae) or a low dose (approximately 30 cercariae) of Schistosoma mansoni, and the development of lung and liver pathology was studied in the subacute (high-dose) and chronic (low-dose) settings.
MEASUREMENTS AND MAIN RESULTS: In the subacute setting, mice showed few eggs in the lungs and no evidence of pulmonary vascular remodeling. In contrast, chronically infected animals had a much greater lung egg burden and developed marked pulmonary vascular remodeling accompanied by perivascular inflammation from 12 weeks onwards. In addition, we observed the presence of plexiform-like lesions in these mice. Lung egg burden correlated with both liver egg burden and right ventricular (RV) index in the chronic group, although significant RV hypertrophy was lacking. Plasma Th1 and Th2 cytokines increased with time in the chronic group and correlated with the degree of pulmonary vascular remodeling.
CONCLUSIONS: This study provides evidence for extensive pulmonary vascular remodeling, despite the absence of RV hypertrophy, in a mouse model of schistosomiasis, including the formation of plexiform-like lesions. Inflammatory cytokines and lung egg burden may contribute to vascular lesion formation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19965814     DOI: 10.1164/rccm.200903-0355OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  47 in total

Review 1.  A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects.

Authors:  Jose Gomez-Arroyo; Sheinei J Saleem; Shiro Mizuno; Aamer A Syed; Harm J Bogaard; Antonio Abbate; Laimute Taraseviciene-Stewart; Yon Sung; Donatas Kraskauskas; Daniela Farkas; Daniel H Conrad; Mark R Nicolls; Norbert F Voelkel
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-02-03       Impact factor: 5.464

2.  Adiponectin decreases pulmonary arterial remodeling in murine models of pulmonary hypertension.

Authors:  Meiqian Weng; Michael J Raher; Patricio Leyton; Terry P Combs; Philipp E Scherer; Kenneth D Bloch; Benjamin D Medoff
Journal:  Am J Respir Cell Mol Biol       Date:  2010-11-12       Impact factor: 6.914

3.  Paigen diet-fed apolipoprotein E knockout mice develop severe pulmonary hypertension in an interleukin-1-dependent manner.

Authors:  Allan Lawrie; Abdul G Hameed; Janet Chamberlain; Nadine Arnold; Aneurin Kennerley; Kay Hopkinson; Josephine Pickworth; David G Kiely; David C Crossman; Sheila E Francis
Journal:  Am J Pathol       Date:  2011-08-09       Impact factor: 4.307

4.  Prolonged activation of IL-5-producing ILC2 causes pulmonary arterial hypertrophy.

Authors:  Masashi Ikutani; Koichi Tsuneyama; Makoto Kawaguchi; Junya Fukuoka; Fujimi Kudo; Susumu Nakae; Makoto Arita; Yoshinori Nagai; Satoshi Takaki; Kiyoshi Takatsu
Journal:  JCI Insight       Date:  2017-04-06

5.  Cytokines, Chemokines, and Inflammation in Pulmonary Arterial Hypertension.

Authors:  Shuxin Liang; Ankit A Desai; Stephen M Black; Haiyang Tang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  Schistosomiasis-induced experimental pulmonary hypertension: role of interleukin-13 signaling.

Authors:  Brian B Graham; Margaret M Mentink-Kane; Hazim El-Haddad; Shawn Purnell; Li Zhang; Ari Zaiman; Elizabeth F Redente; David W H Riches; Paul M Hassoun; Angela Bandeira; Hunter C Champion; Ghazwan Butrous; Thomas A Wynn; Rubin M Tuder
Journal:  Am J Pathol       Date:  2010-07-29       Impact factor: 4.307

7.  17β-Estradiol attenuates hypoxic pulmonary hypertension via estrogen receptor-mediated effects.

Authors:  Tim Lahm; Marjorie Albrecht; Amanda J Fisher; Mona Selej; Neel G Patel; Jordan A Brown; Matthew J Justice; M Beth Brown; Mary Van Demark; Kevin M Trulock; Dino Dieudonne; Jagadeshwar G Reddy; Robert G Presson; Irina Petrache
Journal:  Am J Respir Crit Care Med       Date:  2012-03-01       Impact factor: 21.405

8.  Plexiform lesions in pulmonary arterial hypertension composition, architecture, and microenvironment.

Authors:  Danny Jonigk; Heiko Golpon; Clemens L Bockmeyer; Lavinia Maegel; Marius M Hoeper; Jens Gottlieb; Nils Nickel; Kais Hussein; Ulrich Maus; Ulrich Lehmann; Sabina Janciauskiene; Tobias Welte; Axel Haverich; Johanna Rische; Hans Kreipe; Florian Laenger
Journal:  Am J Pathol       Date:  2011-05-11       Impact factor: 4.307

9.  Severe pulmonary arterial hypertension induced by SU5416 and ovalbumin immunization.

Authors:  Shiro Mizuno; Laszlo Farkas; Aysar Al Husseini; Daniela Farkas; Jose Gomez-Arroyo; Donatas Kraskauskas; Mark R Nicolls; Carlyne D Cool; Herman J Bogaard; Norbert F Voelkel
Journal:  Am J Respir Cell Mol Biol       Date:  2012-07-27       Impact factor: 6.914

10.  Hypothesis: Neuroendocrine Mechanisms (Hypothalamus-Growth Hormone-STAT5 Axis) Contribute to Sex Bias in Pulmonary Hypertension.

Authors:  Pravin B Sehgal; Yang-Ming Yang; Edmund J Miller
Journal:  Mol Med       Date:  2015-07-30       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.